Actively Recruiting
Phase 3 Randomized Trial of Manganese-Primed Immunochemotherapy Versus Placebo With Anti-PD-1 and Chemotherapy in Advanced Ovarian Cancer
Led by Chinese PLA General Hospital · Updated on 2026-09-16
120
Participants Needed
6
Research Sites
88 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of manganese-primed immunochemotherapy in patients with advanced epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer who have relapsed and developed resistance to existing treatments. This phase III trial follows earlier studies that suggested manganese could boost the immune response to anti-PD-1 antibodies combined with chemotherapy, aiming to confirm the treatments effectiveness and safety in improving clinical outcomes. Participants receive either manganese chloride combined with anti-PD-1 antibody, nab-paclitaxel, and platinum chemotherapy, or a placebo combined with the same drugs. Treatments are given every 3 weeks until achieving a second complete response, disease progression, unacceptable side effects, or withdrawal. Manganese and placebo are inhaled twice weekly during cycles. Chemotherapy and antibody drugs are administered intravenously on specific days within each 3-week cycle. During the study, participants will undergo regular assessments including imaging to measure tumor response and progression-free survival over 12 months, along with monitoring for treatment-related side effects. Researchers will also evaluate overall survival and response rates up to 24 months. Safety and lab tests assess organ function and immune status. The trial involves frequent visits for treatment and follow-up, with a study duration lasting until disease progression or other defined endpoints.
CONDITIONS
Brief Title
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
Research Team
W
Weidong Han
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here